Anzeige
+++*** KAUF-ALARM ***: MEGATREND NUTZEN: Neuer Stern am Food-Himmel lockt mit Traum-Renditen! Über 100% bis zum IPO-Preis möglich!+++

Ergomed WKN: A117XM ISIN: GB00BN7ZCY67 Kürzel: 2EM

Kurs zur ERGOMED PLC LS -,01 Aktie
17,68 EUR
-0,56 %-0,10
21. Oct, 09:28:21 Uhr, Lang & Schwarz
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.
Anzeige
Alles ab 0 Euro pro Order. Dauerhaft.
Smartbroker
H
HotStock22 vom 13.10.21 14:43 Uhr
Navigating the Path Towards Decentralized Trials in Oncology: From Technology to AI", this hot topic webinar will occur on 18 November 2021. https://www.bigmarker.com/bioalliance-video-network/Navigating-the-Path-Towards-Decentralized-Trials-in-Oncology-From-Technology-to-AI?show_live_page=true&utm_source=cro+linkedin&utm_medium=social+media&utm_campaign=november+2021+cro+webinar
H
HotStock22 vom 29.09.21 10:23 Uhr
Ergomed reveal 'great progress on delivering on strategy in first half of 2021' https://www.proactiveinvestors.co.uk/companies/news/961530/ergomed-reveal--great-progress-on-delivering-on-strategy-in-first-half-of-2021--961530.html
H
HotStock22 vom 12.08.21 10:52 Uhr
Momentum continues with EBITDA upgrades https://www.edisongroup.com/publication/momentum-continues-with-ebitda-upgrades/29809
H
HotStock22 vom 28.07.21 09:04 Uhr
High sales in H1 2021 and excellent forward visibility Further strategic progress https://www.ergomedplc.com/ergomed-h1-2021-trading-update/
H
HotStock22 vom 27.07.21 10:12 Uhr
Ergomed plc - Trading Update +Total revenue growth of 38.8% over H1 2020 to £56.0 million (up 48.1% in constant currency*) +CRO division delivered strong growth with revenue up 90.7% over H1 2020 to £27.2 million, including the MedSource business acquired in 2020, with like-for-like growth of 16.1% (24.5% in constant currency) https://www.proactiveinvestors.co.uk/LON:ERGO/Ergomed-PLC/rns/1010148
H
HotStock22 vom 13.06.21 10:33 Uhr
FY21e EBITDA ‘materially ahead’ of consensus https://www.edisongroup.com/publication/fy21e-ebitda-materially-ahead-of-consensus/29610
H
HotStock22 vom 01.06.21 16:15 Uhr
M&A remains on the agenda with plenty of firepower https://www.edisongroup.com/publication/whats-next-after-stellar-2020-performance/29566
H
HotStock22 vom 12.05.21 15:10 Uhr
European Mediscience Awards 2021 1. Ergomed has been shortlisted for “Best Communication Award” and “Company of the Year”. http://www.mediscience-event.co.uk/nominations-overview/
H
HotStock22 vom 11.05.21 16:56 Uhr
https://www.ergomedplc.com/mark-enyedy-appointed-to-board-as-non-executive-director/
H
HotStock22 vom 10.05.21 16:12 Uhr
Mark Enyedy Appointed to Board as Non-Executive Director Mr Enyedy brings more than 25 years of senior leadership experience in the biopharmaceutical sector, including executive management, corporate development and legal roles, across multiple therapeutic areas with a focus on rare diseases and oncology. He is currently President and Chief Executive Officer and a Director of ImmunoGen, Inc., a publicly-traded biotechnology company, where he oversees strategy and operations. He is also a member of the Board of Directors of the Biotechnology Innovation Organization (BIO), the world's largest advocacy organisation representing the biotechnology industry in the US and globally. Prior to ImmunoGen, Mr Enyedy served in various executive capacities at Shire plc, including as Executive Vice President and Head of Corporate Development, a role in which he negotiated and integrated the multi-billion dollar acquisitions of NPS Pharmaceuticals and Dyax Corp. and oversaw the $32 billion combination with Baxalta, Inc. Mr Enyedy was also previously President of the Transplant, Oncology and Multiple Sclerosis division at Genzyme Corporation, and under his leadership the division achieved revenue growth from under $10 million to more than $675 million in just seven years. He began his career as an attorney at Palmer & Dodge, a Boston-based law firm where his practice focused on representing biopharmaceutical, high technology, and energy companies in M&A, licensing, and financing transactions. https://www.investegate.co.uk/ergomed-plc--ergo-/rns/board-changes/202105100700089974X/
Kommentare
1 ERGOMED PLC LS -,01 Hauptdiskussion
Geld/Brief Kurse
Börse Geld Brief Zeit Volumen Kurs
Xetra 17,55 18,10 1634732348 20. Oct 1.430 Stk 17,95 EUR
Frankfurt 17,50 17,95 1634796417 08:06 16,70 EUR
Berlin 17,40 17,90 1634800554 09:15 17,65 EUR
Düsseldorf 17,45 17,90 1634799942 09:05 17,40 EUR
München 17,55 17,80 1634796378 08:06 17,75 EUR
Stuttgart 17,55 18,10 1634796078 08:01 17,25 EUR
Tradegate 17,45 17,80 1634761612 20. Oct 1.648 Stk 17,90 EUR
Lang & Schwarz 17,45 17,90 1634801301 09:28 17,68 EUR
London 1634659499 19. Oct 33.917 Stk 15,00 GBP
Gettex 17,45 17,80 1634800381 09:13 17,85 EUR
Baader Bank 17,45 17,80 1634801300 09:28 17,63 EUR
TTMzero 1634801300 09:28 17,63 EUR
ges. 36.995 Stk
Realtime / Verzögert
Börsennotierung
Marktkapitalisierung in EUR
875,4 Mio.
Anzahl der Aktien
48,9 Mio.
Grundlegende Daten zur ERGOMED PLC LS -,01 Aktie
Finanzdaten 2017 2018 2019 2020 2021 2022
Ergebnis je Aktie (bereinigt) - - - - - -
Cashflow - - - - - -
Eigenkapitalquote - - - - - -
Verschuldungsgrad - - - - - -
Eigenkapitalrendite - - - - - -
Gesamtkapitalrendite - - - - - -
EBITDA - - - - - -
EBIT - - - - - -
Fundamentaldaten 2017 2018 2019 2020 2021 2022
Dividendenrendite - - - - - -
Kurs-Gewinn-Verhältnis (KGV) - - - - - -
Dividende je Aktie - - - - - -
Bilanzdaten 2017 2018 2019 2020 2021 2022
Netto-Provisionsüberschuss - - - - - -
Umsatzerlöse - - - - - -
Ergebnis vor Steuern - - - - - -
Steuern - - - - - -
Ausschüttungssumme - - - - - -
Nettoverzinsung - - - - - -
Zinsertrag - - - - - -
Gesamtertrag - - - - - -

Newsletter

Unser Börsendienst gehört mit mehr als 300.000 Abonnenten zu den wichtigsten Börsenmedien in Deutschland.

Newsletter abonnieren

Wir machen die Börse mobil!

Holen Sie sich jetzt die Apps von BörsenNEWS.de und erleben Sie eine Verbindung von Kompaktheit und Detailtiefe, die Sie begeistern wird!

BörsennewsApp
BörsennewsApp im Google Play Store
BörsennewsApp im Apple Store

© 2021 börsennews.de

Daten und Kurse: SIX Financial Information SIX Financial Information

Zeitverzögerung der Kursdaten: Deutsche Börsen +15 Min. NASDAQ +15 Min. NYSE +20 Min. AMEX +20 Min. Dow Jones +15 Min. Alle Angaben ohne Gewähr.